 | • レポートコード：B-MOR-05195 • 出版社/出版日：Mordor Intelligence / 2018年3月 • レポート形態：英文、PDF、110ページ • 納品方法：Eメール（受注後2営業日） • 産業分類：Healthcare |
| Single User（1名様用） | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User（7名様用） | ￥666,000 (USD4,500) | ▷ お問い合わせ |
| Corporate User | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本資料は、ECMO（体外式膜型人工肺）システムの世界市場について調べ、ECMO（体外式膜型人工肺）システムの世界規模、市場動向、市場環境、方法別分析、用途別分析、エンドユーザー別分析、アメリカ市場規模、ヨーロッパ市場規模、アジア市場規模、日本市場規模、中国市場規模、企業の競争環境、関連企業情報などをまとめた調査レポートです。 ・イントロダクション ・エグゼクティブサマリー ・ECMO（体外式膜型人工肺）システムの世界市場インサイト ・ECMO（体外式膜型人工肺）システムの世界市場環境 ・ECMO（体外式膜型人工肺）システムの世界市場動向 ・ECMO（体外式膜型人工肺）システムの世界市場規模 ・ECMO（体外式膜型人工肺）システムの世界市場規模：方法別 ・ECMO（体外式膜型人工肺）システムの世界市場規模：用途別 ・ECMO（体外式膜型人工肺）システムの世界市場規模：エンドユーザー別 ・ECMO（体外式膜型人工肺）システムの世界市場：地域別市場規模・分析 ・ECMO（体外式膜型人工肺）システムの北米市場規模・予測 ・ECMO（体外式膜型人工肺）システムのアメリカ市場規模・予測 ・ECMO（体外式膜型人工肺）システムのヨーロッパ市場規模・予測 ・ECMO（体外式膜型人工肺）システムのアジア市場規模・予測 ・ECMO（体外式膜型人工肺）システムの日本市場規模・予測 ・ECMO（体外式膜型人工肺）システムの中国市場規模・予測 ・ECMO（体外式膜型人工肺）システムのインド市場規模・予測 ・ECMO（体外式膜型人工肺）システムの韓国市場規模・予測 ・関連企業情報・競争状況 |
The global extra corporeal membrane oxygenation system market is expected to register a CAGR of 3.6%, during the forecast period. North America dominates the global market, due to the favorable reimbursement scenario and increasing incidences of lung cancer in the region. Moreover, the presence of large number of ECMO centers in the United States are also contributing to the growth of market.
Increasing incidences of cardiac disorders
Cardiovascular diseases are the leading cause of death globally. According to the WHO in 2017, 17.7 million people died from cardiovascular diseases, accounting for 31% of all global deaths, and 7.4 million people died from coronary heart disease. Factors, such as, increasing use of tobacco and alcohol, unhealthy diet, and physical inactivity are leading to the rise in cardiovascular diseases, further driving the market.
In addition, technological advancement, rising instances of the chronic obtrusive pulmonary disease (COPD), and increased adoption of ECMO machines are fuelling the growth of global ECMO system market.
Risks Associated with ECMO Treatment
The ECMO procedure is used to assist the transition from the cardiopulmonary bypass ventilation, after heart surgery. There are many risks associated with ECMO machines, including bleeding in the skull. The risk of bleeding increasing if a surgical operation is required as the part of the treatment. Most of the times due to the ECMO procedures stroke, arteries or veins are being damaged, that are some of the major risks with ECMO treatment thus restraining growth of the market.
In addition, high costs associated with the ECMO procedures restrict it patients who can afford it. The presence of alternative techniques are also hindering the growth of global ECMO system market.
North America to Dominate the Market
As per the American Heart Association, coronary heart disease is the leading cause of deaths (45.1%), followed by cardiovascular disease in the United States, stroke (16.5%), and heart failure (8.5%). About 5.7 million adults in the United States die of a heart failure every year and ECMO has the potential to reduce the percentage of in-hospital failures. Thus, increasing adoption is fuelling the growth of global ECMO market in that region.
Key Developments in the Market
• July, 2017 – Castor Branched Aortic Stent-Graft System receives approval from China Food and Drug Administration (CFDA) on 11 July 2017.
Major Players – ALUNG TECHNOLOGIES INC., EUROSETS, GETINGE GROUP, LIVANOVA PLC, MEDTRONIC, MICROPORT SCIENTIFIC CORPORATION, NIPRO MEDICAL CORPORATION, TERUMO MEICAL CORPORATION, THORATEC, and XENIOS AG, amongst others.
Reasons to Purchase the Report
• Current and future ECMO system market outlook in the developed and emerging markets
• Analyzing various perspectives of the market with the help of Porter’s five forces analysis
• The segment that is expected to dominate the market
• Regions that are expected to witness the fastest growth during the forecast period
• Identify the latest developments, market shares, and strategies employed by the major market players.
• 3 months analyst support, along with the Market Estimate sheet in excel.
Customization of the Report
• This report can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
レポート目次1. Introduction
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter’s Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Product and Services
5.2.5 Competitive Rivalry Within the Industry
6. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 Increasing Incidences of Cardiac Disorders
6.1.2 Technological Advancements
6.1.3 Rising Incidence in Chronic Obtrusive Pulmonary Diseases (COPD)
6.1.4 Increased Adoption of ECMO machines
6.2 Market Restraints
6.2.1 Risks Associated with ECMO Treatment
6.2.2 Presence of Alternative Techniques
6.2.3 High Cost of ECMO Procedures
6.3 Opportunities
6.4 Key Challenges
7. Market Segmentation
7.1 By Method
7.1.1 Veno-Arterial (VA)
7.1.2 Veno-Venous (VV)
7.1.3 Others
7.2 By Application
7.2.1 Cardiac
7.2.2 Respiratory
7.2.3 Extracorporeal Cardiopulmonary Resuscitation (ECPR)
7.3 By End User
7.3.1 Neonatal
7.3.2 Pediatric
7.3.3 Adults
7.4 By Geography
7.4.1 North America
7.4.1.1 United States
7.4.1.2 Canada
7.4.1.3 Mexico
7.4.2 Europe
7.4.2.1 France
7.4.2.2 Germany
7.4.2.3 United Kingdom
7.4.2.4 Italy
7.4.2.5 Spain
7.4.2.6 Rest of Europe
7.4.3 Asia-Pacific
7.4.3.1 China
7.4.3.2 Japan
7.4.3.3 India
7.4.3.4 Australia & New Zealand
7.4.3.5 South Korea
7.4.3.6 Rest of Asia-Pacific
7.4.4 Middle East & Africa
7.4.4.1 GCC
7.4.4.2 South Africa
7.4.4.3 Rest of Middle East & Africa
7.4.5 South America
7.4.5.1 Brazil
7.4.5.2 Argentina
7.4.5.3 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Products Launches
9. Key Players
9.1 Alung Technologies Inc.
9.2 Eurosets
9.3 Getinge Group
9.4 Livanova Plc
9.5 Medtronic
9.6 Microport Scientific Corporation
9.7 Nipro Medical Corporation
9.8 Terumo Meical Corporation
9.9 Thoratec
9.10 Xenios AG
9.11 List Not Exhuastive
10. Future Outlook of the Market